

AMENDMENTS TO THE CLAIMS

1-17. (Canceled).

18. (Currently Amended) A method of reducing the weight of an overweight subject, said method comprising: identifying an overweight subject and administering to an~~an~~said overweight subject a pharmaceutical composition comprising zonisamide, or a pharmaceutically acceptable salt thereof, in an amount effective to reduce the weight of said subject .

19. (Previously Presented) The method according to claim 18, wherein said effective amount of zonisamide is in the range of about 50 to about 1000 mg/day.

20. (Previously Presented) The method according to claim 19, wherein said effective amount of zonisamide is in the range of about 100 to about 600 mg/day.

21. (Previously Presented) The method according to claim 18, wherein said overweight subject is an obese subject.

22. (Previously Presented) The method according to claim 18 wherein said pharmaceutical compositions is administered by a route selected from the group consisting of oral, parenteral, topical, injection and rectal administration.

23. (Previously Presented) The method according to claim 22, wherein said pharmaceutical composition is administered orally to said subject.

24. (Previously Presented) The method according to claim 18, wherein said pharmaceutical composition is administered in combination with another therapeutic method commonly used to reduce weight.

25. (Previously Presented) The method according to claim 24, wherein said pharmaceutical composition is administered in combination with a reduced calorie diet or increased physical activity.

26. (Previously Presented) The method according to claim 24, wherein said pharmaceutical composition is administered in combination with orlistat, phentermine, sibutramine, topiramate, or sibutramine hydrochloride.

27-34. (Canceled).

35. (Currently Amended) A method of reducing weight in an overweight subject, said method comprising: identifying an overweight subject and administering to an~~an~~said overweight subject a pharmaceutical composition comprising zonisamide, or a pharmaceutically acceptable

salt thereof, in an amount effective to induce weight loss in said subject, wherein the weight loss is $\geq 5\%$, or wherein said weight loss continues during the period of administration of said composition comprising zonisamide or a pharmaceutically acceptable salt thereof.

36. (Previously Presented) The method according to claim 35, wherein said effective amount of zonisamide is in the range of about 50 to about 100 mg/day.

37. (Previously Presented) The method according to claim 35, wherein said effective amount of zonisamide is in the range of about 100 to about 600 mg/day.

38. (Previously Presented) The method according to claim 35, wherein said overweight subject is an obese subject.

39. (Previously Presented) The method according to claim 35, wherein said pharmaceutical composition is administered by a route selected from the group consisting of oral, parenteral, topical, injection and rectal administration.

40. (Previously Presented) The method according to claim 39, wherein said pharmaceutical composition is administered orally to said subject.

41. (Previously Presented) The method according to claim 35, wherein said pharmaceutical composition is administered in combination with another therapeutic method commonly used to reduce weight.

42. (Previously Presented) The method according to claim 41, wherein said pharmaceutical composition is administered in combination with a reduced calorie diet or increased physical activity.

43. (Previously Presented) The method according to claim 42, wherein said pharmaceutical composition is administered in combination with orlistat, phentermine, sibutramine, topiramate, or sibutramine hydrochloride.

44. (Currently Amended) A method of treating obesity by reducing the weight of an obese subject, said method comprising: identifying an obese subject and administering to an said obese subject an effective amount of a pharmaceutical composition comprising zonisamide, or a pharmaceutically acceptable salt thereof.

45. (Previously Presented) The method according to claim 44, wherein said effective amount of zonisamide is in the range of about 50 to about 100 mg/day.

46. (Previously Presented) The method according to claim 44, wherein said effective amount of zonisamide is in the range of about 100 to about 600 mg/day.

47. (Previously Presented) The method according to claim 44, wherein said obese subject has a BMI of at least 30 kg/m².

48. (Previously Presented) The method according to claim 44, wherein said pharmaceutical composition is administered by a route selected from the group consisting of oral, parenteral, topical, injection and rectal administration.

49. (Previously Presented) The method according to claim 48, wherein said pharmaceutical composition is administered orally to said subject.

50. (Previously Presented) The method according to claim 44, wherein said pharmaceutical composition is administered in combination with another therapeutic method commonly used to reduce weight.

51. (Previously Presented) The method according to claim 50, wherein said pharmaceutical composition is administered in combination with a reduced calorie diet or increased physical activity.

52. (Previously Presented) The method according to claim 51, wherein said pharmaceutical composition is administered in combination with orlistat, phentermine, sibutramine, topiramate, or sibutramine hydrochloride.

53. (New) A method of treating obesity by reducing the weight of an obese subject, said method comprising: identifying an obese subject and orally administering to said obese subject a capsule comprising a pharmaceutical composition comprising zonisamide or a pharmaceutically acceptable salt thereof, wherein said subject receives a daily dose of 100 to 600 mg of zonisamide.